Dermasensor is a non-invasive, handheld device designed for the early detection of skin cancer.
It utilizes spectroscopy to analyze the molecular composition of skin lesions.
By emitting light and measuring the reflected spectra, the device can identify abnormal cellular structures indicative of malignancy.
It can assist clinicians in making more accurate and timely decisions regarding the need for biopsy or further dermatological evaluation.
While Dermasensor can aid in the assessment of suspicious lesions, it should not replace histopathological examination, which remains the gold standard for definitive diagnosis of skin cancer.
The device uses Elastic Scattering Spectroscopy (ESS), which directs light onto the skin and measures how it scatters when it hits different tissue structures.
When placed on a suspicious lesion, the Dermasensor emits light wavelengths into the skin, which is then analyzed as how cellular structures scatter and absorb the light
Different cell structures (cancerous vs. non-cancerous) have distinct optical signatures.
The collected data produces a risk assessment to inform clinicians whether a lesion has a higher likelihood of being cancerous and requiring further evaluation.
The device has shown sensitivity rates of over 90% for melanoma detection in some studies.
Specificity rates vary but generally fall between 30-50% for non-melanoma skin cancers.
It can help reduce unnecessary biopsies by helping physicians better identify truly suspicious lesions
The integration of AI has enhanced the device’s accuracy by appreciating spectral differences invisible to human interpretation.
AI can accounting for variations in skin types and lesion presentations,, and identifying specific cancer subtypes based on their unique optical signatures